In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of:The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TCThe 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TCAn extension of the FLAIR study, evaluating efficacy and safety of long-acting CAB plus RPV in treatment-naive patientsThe CUSTOMIZE study, an implementation effectiveness study that evaluated the feasibility of implementing provision of long-acting CAB plus RPV in the clinic settingThe HPTN 084 study of PrEP using CAB vs TDF plus FTC in sexually active cisgender womenThe CALIBRATE and CAPELLA studies of long-acting lenacapavir in treatment-naive and treatment-experienced patients, respectivelyIn addition, Drs. Cocohoba and Schafer discuss key considerations of these medications, including cost and acquisition logistics.Presenters:Jennifer Cocohoba, PharmDProfessorDepartment of Clinical PharmacyUniversity of California, San FranciscoSan Francisco, CaliforniaJason Schafer, PharmDProfessor and Vice ChairJefferson College of PharmacyThomas Jefferson UniversityPhiladelphia, PennsylvaniaContent based on conference coverage of IAS 2021 with educational rant support from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp.; and ViiV Healthcare.Link to full program:https://bit.ly/3z8SBnC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related